Literature DB >> 28650877

The resurgence of botulinum toxin injection for strabismus in children.

Marielle Mahan1, J Mark Engel.   

Abstract

PURPOSE OF REVIEW: The present review discusses recent advances in the use of botulinum toxin for the management of strabismus in children. RECENT
FINDINGS: Botulinum toxin injection produces similar results compared to surgery for certain subtypes of strabismus, especially acute onset esotropia. It may be more effective in many subtypes of esotropia where surgery has been less reliable, including partially accommodative esotropia, esotropia associated with cerebral palsy, and thyroid eye disease.
SUMMARY: Small retrospective studies have demonstrated the efficacy of botulinum toxin in the treatment of many types of pediatric strabismus, providing some guidance for clinicians to determine which patients would benefit most from this intervention. Although administration of botulinum toxin is generally accepted as a reasonable option in select cases, many strabismus surgeons have not fully embraced the treatment, in part because of perceived disadvantages compared to surgery and difficulty in identifying subsets with the highest potential for therapeutic success. A recent study compared the administration of botulinum toxin in children with acute-onset esotropia to surgical correction and found botulinum toxin had a statistically equal success rate, but with the advantage of significantly less time under general anesthesia. In addition, botulinum toxin has been recently tried in patients with partially accommodative esotropia, esotropia associated with cerebral palsy, cyclic esotropia, and in patients with thyroid eye disease. The present review will discuss current clinical recommendations based on recent studies on the use of botulinum toxin in children with strabismus.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28650877     DOI: 10.1097/ICU.0000000000000408

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  7 in total

1.  Botulinum toxin for the treatment of cyclic esotropia in a child with Chiari type I malformation.

Authors:  Inae E Jang; John A Davis; K David Epley; Michelle T Cabrera
Journal:  J AAPOS       Date:  2020-04-07       Impact factor: 1.220

Review 2.  Interventions for eye movement disorders due to acquired brain injury.

Authors:  Fiona J Rowe; Kerry Hanna; Jennifer R Evans; Carmel P Noonan; Marta Garcia-Finana; Caroline S Dodridge; Claire Howard; Kathryn A Jarvis; Sonia L MacDiarmid; Tallat Maan; Lorraine North; Helen Rodgers
Journal:  Cochrane Database Syst Rev       Date:  2018-03-05

3.  Involvement of dysregulated coding and long non‑coding RNAs in the pathogenesis of strabismus.

Authors:  Wen-Xiu Ma; Xiao-Gang Huang; Tian-Ke Yang; Jing-Yan Yao
Journal:  Mol Med Rep       Date:  2018-03-29       Impact factor: 2.952

4.  Comparison of the therapeutic effects of surgery following prism adaptation test versus surgery alone in acute acquired comitant esotropia.

Authors:  Peng Zhang; Ying Zhang; Lei Gao; Jun Yang
Journal:  BMC Ophthalmol       Date:  2020-07-23       Impact factor: 2.209

5.  Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis.

Authors:  Steffen Berweck; Marta Banach; Deborah Gaebler-Spira; Henry G Chambers; A S Schroeder; Thorin L Geister; Michael Althaus; Angelika Hanschmann; Matteo Vacchelli; Michaela V Bonfert; Florian Heinen; Edward Dabrowski
Journal:  Toxins (Basel)       Date:  2022-08-25       Impact factor: 5.075

6.  Botulinum toxin chemodenervation for childhood strabismus in England: National and local patterns of practice.

Authors:  Ameenat Lola Solebo; Anne-Marie Austin; Maria Theodorou; Chris Timms; Joanne Hancox; Gillian G W Adams
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

7.  BOTOX injection to treat strabismus after infant botulism type B infection.

Authors:  Sarah G Bonaffini; Victoria Cocozza; Jing Jin
Journal:  Am J Ophthalmol Case Rep       Date:  2020-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.